Changes in US stocks | Diet drug concept stocks strengthened, and Shodi Biotech (GPCR.US) rose more than 5%

The Zhitong Finance App learned that on Wednesday, US diet drug concept stocks strengthened. As of press release, Shuodi Biotech (GPCR.US) had risen more than 5%, Novo Nordisk (NVO.US) had risen more than 3.5%, Roche (RHHBY.US) had risen more than 3%, and Lily.US (LY.US) had risen slightly. According to the news, Schudi Biotech previously announced that its daily oral administration of the small molecule GLP-1 receptor agonist Aleniglipron had positive top-line results in the Access clinical project.